Monopar Therapeutics (Monopar Therapeutics) Other Stockholders Equity : $0.00 Mil (As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Monopar Therapeutics Other Stockholders Equity?

Monopar Therapeutics's Other Stockholders Equity for the quarter that ended in Mar. 2024 was $0.00 Mil.

Monopar Therapeutics's quarterly Other Stockholders Equity declined from Sep. 2023 ($0.00 Mil) to Dec. 2023 ($-0.00 Mil) but then increased from Dec. 2023 ($-0.00 Mil) to Mar. 2024 ($0.00 Mil).

Monopar Therapeutics's annual Other Stockholders Equity increased from Dec. 2021 ($-0.00 Mil) to Dec. 2022 ($0.00 Mil) but then declined from Dec. 2022 ($0.00 Mil) to Dec. 2023 ($-0.00 Mil).

Monopar Therapeutics Other Stockholders Equity Historical Data

The historical data trend for Monopar Therapeutics's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Monopar Therapeutics Other Stockholders Equity Chart

Monopar Therapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Stockholders Equity

Get a 7-Day Free Trial

Monopar Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Other Stockholders Equity	Get a 7-Day Free Trial															-	-	-	-	-

Monopar Therapeutics Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

Monopar Therapeutics Other Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Monopar Therapeutics's Other Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Monopar Therapeutics (Monopar Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Monopar Therapeutics Inc (NAS:MNPR) » Definitions » Other Stockholders Equity

Comparable Companies

Traded in Other Exchanges

1IY:Germany

Address

1000 Skokie Boulevard, Suite 350, Wilmette, IL, USA, 60091

Website

https://www.monopartx.com

Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of?Validive?for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicin?for the treatment?of advanced soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for advanced cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.

Executives

Michael J Brown	director	C/O EURONET WORLDWIDE, INC., 11400 TOMAHAWK CREEK PARKWAY, SUITE 300, LEAWOOD KS 66211
Arthur J Klausner	director	ONE PALMER SQUARE, PRINCETON NJ 08542
Raymond Anderson	director	C/O MONOPAR THERAPEUTICS INC., 1000 SKOKIE BLVD., SUITE 350, WILMETTE IL 60091
Kim R Tsuchimoto	officer: Chief Financial Officer	C/O MONOPAR THERAPEUTICS INC., 1000 SKOKIE BLVD., SUITE 350, WILMETTE IL 60091
Chandler Robinson	director, officer: Chief Executive Officer	C/O SKOKIE BLVD., SUITE 350, WILMETTE IL 60091
Andrew Cittadine	officer: Chief Operating Officer	C/O 1000 SKOKIE BLVD SUITE 350, WILMETTE IL 60091
Patrice Rioux	other: Acting Chief Medical Officer	C/O MONOPAR THERAPEUTICS INC, 1000 SKOKIE BLVD., SUITE 350, WILMETTE IL 60091
Christopher M Starr	director	C/O MONOPAR THERAPEUTICS INC, 1000 SKOKIE BLVD., SUITE 350, WILMETTE IL 60091
Filho Jose Octavio Pinto Costa	officer: Chief Medical Officer	C/O 1000 SKOKIE BLVD SUITE 350, WILMETTE IL 60091
Tactic Pharma Llc	10 percent owner	C/O SKOKIE BLVD., SUITE 350, WILMETTE IL 60091
Diane Hendricks	10 percent owner	C/O GEM PHARMACEUTICALS, 200 RANDOLPH AVE., HUNTSVILLE AL 35801
Karl Leo	10 percent owner	C/O GEM PHARMACEUTICALS, 200 RANDOLPH AVE., HUNTSVILLE AL 35801
Kirsten Anderson	officer: SVP, Clinical Development	C/O SKOKIE BLVD., SUITE 350, WILMETTE IL 60091
Gem Pharmaceuticals Llc	10 percent owner	C/O 1000 SKOKIE BLVD., SUITE 350, WILMETTE IL 60091
Tacticgem Llc	10 percent owner	1000 SKOKIE BLVD., SUITE 350, WILMETTE IL 60091